About Ology Bio
Ology Bio is a Healthcare company based in Alachua (United States) founded in 1999, and was acquired by Resilience in April 2021. Biologics-focused contract development and manufacturing organization (CDMO). Its chief executive, as recorded, is Peter Khoury. Its focus areas include Biopharma Outsourcing, CDMO and Biologics. Its competitors include KBI Biopharma, Aldevron and Omnia Biologics; 2 of its 3 listed competitors have raised funding.
Company details
Ology Bioservices (formerly Nanotherapeutics) is a biologics-focused contract development and manufacturing organization (CDMO) serving both government and commercial clients. It offers services such as process development, cell line development, cGMP manufacturing, analytical regulatory for recombinant proteins, monoclonal antibodies, viral vaccines, and gene therapy drug products. The company has developed proprietary vaccine delivery technologies and platform expression systems. The company uses their proprietary Vero Cell vaccine manufacturing cell line acquired from BaxaltaBaxter Vaccines for the development of inactivated whole virus vaccines. It offers mammalian cell line development capabilities. The company has a BSL-3 cGMP compliant vaccines manufacturing facility called Advanced Development and Manufacturing (ADM) facility. The company has several vaccine programs available for partnering andor licensing such as ross river (phase III), chikungunya, pandemic and seasonal flu vaccines, yellow fever (MVA), typhoid, West Nile and norovirus.
- Headquarters Alachua, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website ologybio.com
- Social LinkedIn X Facebook
- Acquired by Resilience (Apr 2021)
- Latest Funding Round$8.4M (USD), Grant
Aug 2018
- InvestorsNIH
& 8 more
- Acquired byResilience
(Apr 2021)
Funding Insights of Ology Bio
- Total Rounds 7
- Last Round Grant — $8.4M
- Investors Count 8
All 7 funding rounds of Ology Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2018 | $8.4M | Grant | – | – | |
| Mar 2018 | Private Equity Round | – | – | ||
| Mar 2015 | $28.5M | Debt – Conventional | – | – | |
| Sep 2014 | $8M | Debt – Conventional | – | – | |
| Jun 2014 | $30M | Debt – Conventional | – | – | |
| Jan 2006 | $5.6M | Grant | – | – | |
| Jun 2005 | Grant | – | – |
9 investors in total: 9 institutional.
Investors in Ology Bio
Ology Bio has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Hercules Capital and US Navy.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| ghitfund.org | ||||
Venture debt and equipment financing are provided to growth-stage companies. | 2008 | trinitycap.com | Phoenix, United States | |
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
| 1958 | darpa.mil | United States | ||
Offers customized capital and lending products to support business growth needs. | 2007 | whiteoaksf.com | San Francisco, United States | |
Naval defense operations are conducted for national security. | 1794 | navy.mil | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Scientific research on drug use and addiction is supported. | drugabuse.gov | United States | ||
Supply chain services for biopharma sector are provided. | 1995 | resilience.com | San Diego, United States |
Investor details for Ology Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ology Bio
25 people are tracked at Ology Bio (8 in leadership, 16 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Peter Khoury | CEO & President | Leadership |
Junan Guo | Chief Quality Officer | Leadership |
William S. Marth | President & CEO | Leadership |
Jimmy Wang | Chief Information Officer | Leadership |
Andrew Montone | Chief Financial Officer, Interim | Leadership |
Susan Billings | Chief Commercial Officer | Leadership |
Ori Solomon | Chief Legal Officer | Leadership |
Mara Strandlund | Chief People Officer | Leadership |
Robert Nelsen | Chairman | Board & advisors |
Beverly L. Davidson | Advisor | Board & advisors |
Mark McClellan | Advisor | Board & advisors |
George Barrett | Board Member | Board & advisors |
Joseph Robert Kerrey | Board Member | Board & advisors |
Mitchell E. Daniels | Board Member | Board & advisors |
Charlie Cooney | Advisor | Board & advisors |
Drew Oetting | Board Member | Board & advisors |
Frances Arnold | Board Member | Board & advisors |
Patrick Y. Yang | Vice Chairman | Board & advisors |
David Schenkein | Advisor | Board & advisors |
Scott Gottlieb | Board Member | Board & advisors |
5 more people are available in the full profile.
Complete people profiles for Ology Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ology Bio
4 dated milestones of Ology Bio across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Ology Bio is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $8.4M.
- Exit Acquired by Resilience.
Competitors of Ology Bio
Ology Bio has 3 listed competitors in our database, 2 of them funded. They include KBI Biopharma, Aldevron and Omnia Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kbibiopharma.com | 1996 | Durham, United States | $17M | 1,243 | Provider of protein formulation, process & cell line development, and cGMP services | |
| aldevron.com | 1998 | Fargo, United States | 747 | Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications | ||
| omniabio.com | 2001 | Rockville, United States | $25.4M | Process development and manufacturing services for biologics are provided. |
Detailed competitors of Ology Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Ology Bio (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ology Bio
Complete news archive for Ology Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ology Bio
Ology Bio was founded in 1999 and raised its 1st funding round 6 years after it was founded.
Ology Bio is headquartered in Alachua, United States. It is registered at Alachua, Florida, United States.
Peter Khoury is the CEO of Ology Bio, as recorded in our data.
Ology Bioservices (formerly Nanotherapeutics) is a biologics-focused contract development and manufacturing organization (CDMO) serving both government and commercial clients. It offers services such as process development, cell line development, cGMP manufacturing, analytical regulatory for recombinant proteins, monoclonal antibodies, viral vaccines, and gene therapy drug products. The company has developed proprietary vaccine delivery technologies and platform expression systems. The company uses their proprietary Vero Cell vaccine manufacturing cell line acquired from BaxaltaBaxter Vaccines for the development of inactivated whole virus vaccines. It offers mammalian cell line development capabilities. The company has a BSL-3 cGMP compliant vaccines manufacturing facility called Advanced Development and Manufacturing (ADM) facility. The company has several vaccine programs available for partnering andor licensing such as ross river (phase III), chikungunya, pandemic and seasonal flu vaccines, yellow fever (MVA), typhoid, West Nile and norovirus.
Ology Bio's top competitors include KBI Biopharma, Aldevron and Omnia Biologics.
Ology Bio has 9 investors. Key investors include NIH, Hercules Capital, US Navy, Resilience, and DARPA.
Yes. Ology Bio was acquired by Resilience in April 2021.